Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA14161Y2006
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00M0GNP68
CRDL
Cardiol Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Cardiol Therapeutics Inc
ISIN
CA14161Y2006
TICKER
CRDL
MIC
XTSX
REUTERS
CRDL.TO
BLOOMBERG
CRDL CN
Mi., 28.09.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today t...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 03.08.2022       Cardiol Therapeutics
CA14161Y2006

Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patientsOakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an a...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.06.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 29, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announ...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 27.06.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is ple...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.06.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 9, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular disease, is pleased to announce that it h...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.05.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that its...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 17.05.2022       Cardiol Therapeutics
CA14161Y2006

Third IND authorization for CardiolRx™ in cardiovascular diseaseStudy to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indicationsOakville, Ontario--(Newsfile Corp. - May 17, 2022) - Cardiol Therapeutics Inc. (NASDA...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 24.03.2022       Cardiol Therapeutics
CA14161Y2006

Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditisMade strategic appointments to...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 22.03.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that Cardiol's Chief Medical Off...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 15.03.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce that its Board of...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 01.03.2022       Cardiol Therapeutics
CA14161Y2006

LANCER Trial expanded to include up to 20 Additional Clinical Research CentersOakville, Ontario--(Newsfile Corp. - March 1, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatmen...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 19.01.2022       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Rid...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.11.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, announced today the closing of its previously announced public offering (the...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 25.10.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has received approval from Health...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 18.10.2021       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - October 18, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage bi...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.09.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it will present at the 2021 Cantor Virtual...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 10.09.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 10, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces the acceleration of the expiry date of all outstandin...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.09.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the appointment of Michael J. Willner, Es...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.08.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the U.S. Food and Drug Administration...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.08.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has received final approval from The Nasdaq Capital Market...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 07.07.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that its Board of Directors has appointed...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 30.06.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces results from its Annual General and Special Me...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 28.06.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the Company's virtual Annual...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 12.05.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the closing of its previously announced "bought deal" short f...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 28.04.2021       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - April 28, 2021) -  Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a cli...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 12.04.2021       Cardiol Therapeutics
CA14161Y2006

Results expected to support the Company's plans to file an IND application with the FDA for a Phase II international trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - April 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developi...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 01.04.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Managem...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 30.03.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that Dr. Andrew Hamer has joined the Com...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 02.03.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - Dienstag, 2. März 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" oder das "Unternehmen"), ein Biotechnologieunternehmen im klinischen Stadium mit Fokus auf der Entwicklung innovativer entzündungshemmender Therapien zur Behandlung von Herz-Kreislauf-Erkrankungen gab heute...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 02.03.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - March 2, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has submitted an application to u...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.01.2021       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - January 21, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage bi...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 07.01.2021       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsley, President and CEO of Cardiol, will participate in the followin...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 22.12.2020       Cardiol Therapeutics
CA14161Y2006

Study results are expected to support the Company's plans to file an IND application with the FDA for a Phase II clinical trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - December 22, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 15.12.2020       Cardiol Therapeutics
CA14161Y2006

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease now being initiated at clinical centers in the United StatesOakville, Ontario--(Newsfile Corp. - December 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OT...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 20.10.2020       Cardiol Therapeutics
CA14161Y2006

The first pharmaceutically produced THC-free* extra-strength cannabidiol (CBD)Oakville, Ontario--(Newsfile Corp. - October 20, 2020) -  Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased t...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - September 30, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outcomes for COVID-19 patients. The US Food and Drug Adminis...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 25.09.2020       Cardiol Therapeutics
CA14161Y2006

Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD)Oakville, Ontario--(Newsfile Corp. - September 25, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or t...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 16.09.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - September 16, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) initiation of a Phase 1 clinical study, intended to assess t...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 15.09.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, announces that Cardiol's President and CEO,...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 26.08.2020       Cardiol Therapeutics
CA14161Y2006

Study Designed to Support Cardiol Therapeutics' Phase 2 International Trial in Acute MyocarditisOakville, Ontario--(Newsfile Corp. - August 26, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular disease...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 05.08.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - August 5, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing how the past success of the orphan drug designation informs Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) eff...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.07.2020       Cardiol Therapeutics
CA14161Y2006

Redondo Beach, California--(Newsfile Corp. - July 15, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the connection between heart disease, COVID-19, and inflammation. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF),...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 29.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has appointed Steven Grasso as Business A...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 25, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), today announced that David Elsley, President and CEO of Cardiol, has filed an early warning report (the "Report") in respect of his ownership of class A common shares of the Company (the "Shares") under the Comp...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 4, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the closing of its previously announced "bought deal" short form pro...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - June 2, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, announces results from its Annual General Meeting ("AGM") of shareholders h...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 29.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it will webcast the Company's virtual Annua...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 14.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 14, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with a syn...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 13, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with Canaccord...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2020       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - May 6, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the filing of a new patent application covering the us...
Zur Nachricht
Cardiol Therapeutics
Charts & Research Termsheets Terminal
Permalink